Table 1.
Difference in patients’ backgrounds among the 3 cohorts
| (Timing of ARSI administration) Median PSA (range) | Cohort A (PSA 0.5–2.0 ng/mL) 1.11 ng/mL (0.51–1.97) | Cohort B (PSA 2.0–4.0 ng/mL) 3.05 ng/mL (2.01–4.00) | Cohort C (PSA > 4.0 ng/mL) 7.40 ng/mL (4.05–28.5) | p-value | ||
|---|---|---|---|---|---|---|
| A vs. B | B vs. C | A vs.C | ||||
| N | 32 | 24 | 41 | |||
| Median Age (range) | 77.4 years (64–89) | 75.3 years (58–89) | 81.3 years (55–94) | 0.529 | 0.081 | 0.099 |
| Median PSA at diagnosis (range) | 10.7 ng/mL (2.0–192) | 20.0 ng/mL (4.9–186) | 14.4 ng/mL (5.0–194) | 0.353 | 0.653 | 0.240 |
| Clinical stage at diagnosis | 0.890 | 0.451 | 0.193 | |||
| cT1-3aN0M0 | 13 (43%) | 11 (50%) | 22 (61%) | |||
| cT3bN0M0 | 9 (30%) | 6 (27%) | 5 (14%) | |||
| cT2-3N1M0 | 8 (27%) | 5 (23%) | 7 (19%) | |||
| Unknown(M0) | 2 | 2 | 5 | |||
| Gleason grade group at diagnosis | 0.600 | 0.302 | 0.655 | |||
| 1–3 | 13 (43%) | 10 (42%) | 18 (53%) | |||
| 4 | 5 (17%) | 2 (8%) | 5 (15%) | |||
| 5 | 12 (40%) | 12 (50%) | 10 (29%) | |||
| Unknown | 2 | 7 | ||||
| Primary treatment | 0.736 | 0.977 | 0.794 | |||
| Surgery | 12 (38%) | 9 (38%) | 15 (37%) | |||
| Radiation | 12 (38%) | 7 (29%) | 13 (32%) | |||
| Androgen deprivation | 8 (25%) | 8 (33%) | 13 (32%) | |||
| Median PSA doubling time (range) | 6.6 months (1.0–20.5) | 4.5 months (1.3–13.4) | 6.2 months (1.0–20.7) | 0.275 | 0.308 | 0.859 |
ARSI androgen receptor signaling inhibitor; PSA prostate-specific antigen